semaglutide huetter Semaglutide Receives FDA Approval for

SLIP adds a powerful approach to the proximity-induced pharmacology (PIP) toolbox, enabling future effector ligand discovery to fully enable TPD and other emerging PIP modalities

Those are not the same as an approved patient label

In this trial, treatment with cagrilintide resulted in significant weight loss compared to placebo, with greater reductions observed at all used cagrilintide doses (0.34.5 mg

Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with weight-related comorbidities